The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection
PHASE1CompletedINTERVENTIONAL
Enrollment
12
Participants
Timeline
Start Date
Not specified
Conditions
HIV Infections
Interventions
DRUG
Thymalfasin
DRUG
Interleukin-2, Polyethylene Glycolated
DRUG
Zidovudine
Trial Locations (1)
943055107
Stanford Univ Med Ctr, Stanford
All Listed Sponsors
lead
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
NCT00001036 - The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection | Biotech Hunter | Biotech Hunter